var data={"title":"Topiramate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Topiramate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7074?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=topiramate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Topiramate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=topiramate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Topiramate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229206\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Qudexy XR;</li>\n      <li>Topamax;</li>\n      <li>Topamax Sprinkle;</li>\n      <li>Topiragen [DSC];</li>\n      <li>Trokendi XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229207\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Topamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229242\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229211\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects. (In clinical trials, adult doses were withdrawn by decreasing in weekly intervals of 50 to 100 mg daily gradually over 2 to 8 weeks for seizure treatment, and by decreasing in weekly intervals by 25 to 50 mg daily for migraine prophylaxis.) Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Epilepsy, monotherapy:</b> Partial-onset seizure and primary generalized tonic-clonic seizure: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 25 mg twice daily; may increase weekly by 50 mg daily up to 100 mg twice daily (week 4 dose); thereafter, may further increase weekly by 100 mg daily up to the recommended dose of 200 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 50 mg daily for 1 week; may increase weekly by 50 mg daily up to 200 mg once daily (week 4 dose); thereafter, may further increase weekly by 100 mg daily up to the recommended dose of 400 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Epilepsy, adjunctive therapy:</b> Partial-onset seizure, primary generalized tonic-clonic seizure, or Lennox-Gastaut syndrome: Oral: <b>Note:</b> Doses &gt;1600 mg have not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 25 mg once or twice daily for 1 week; may increase weekly by 25 to 50 mg daily until response; usual maintenance dose: 100 to 200 mg twice daily (partial-onset seizures or Lennox-Gastaut syndrome) or 200 mg twice daily (primary generalized tonic-clonic seizures). Doses &gt;400 mg have not shown additional benefit for treatment of partial-onset seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 25 to 50 mg once daily for 1 week; may increase weekly by 25 to 50 mg daily until response; usual maintenance dose: 200 to 400 mg once daily (partial-onset seizures, Lennox-Gastaut syndrome) or 400 mg once daily (primary generalized tonic-clonic seizures). Doses &gt;400 mg daily have not shown additional benefit for treatment of partial-onset seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Migraine prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 25 mg once daily (in evening); may increase weekly by 25 mg daily up to the recommended dose of 100 mg daily given in 2 divided doses. Increased intervals between dose adjustments may be considered. Doses &gt;100 mg daily have shown no additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 25 mg once daily; increase based on response and tolerability in weekly increments of 25 mg to the recommended dose of 100 mg once daily. Increased intervals between dose adjustments may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Alcohol dependence (off-label use):</b> Oral: Initial: 25 mg once daily; increase dose weekly to a maximum of 300 mg/day in 2 divided doses by weeks 5 to 14 (Johnson 2007) or weeks 8 to 12 (Johnson 2003; Johnson 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Antipsychotic-induced weight gain (off-label use):</b> Oral: Initial: 25 mg twice daily for one week; continue to increase in increments of 25 to 50 mg each week based on response and tolerability up to 300 mg/day. Target doses in clinical trials ranged from 100 to 300 mg/day (Ko 2005; Mahmood 2013; Narula 2010; Nickel 2005b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Binge eating disorder (off-label use):</b> Oral: Initial: 25 mg once daily; titrate to a target dose of 400 mg/day (McElroy 2007). Dosage increases were made weekly in progressively larger increments ranging from 25 to 100 mg/day; doses were divided twice daily. Higher doses were not well tolerated (McElroy 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Borderline personality disorder (off-label use)</b>: Oral: Initial: 25 to 50 mg/day; increase in increments of 25 to 50 mg each week based on response and tolerability up to a target dose of 200 to 250 mg/day (Loew 2006; Nickel 2004; Nickel 2005a). Additional data may be necessary to further define the role of topiramate in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Bulimia nervosa (off-label use):</b> Oral: Initial: 25 mg once daily for week 1; titrate at weekly intervals in 25 to 50 mg increments to the minimal effective dose or a maximum of 400 mg/day (Hedges 2003; Hoopes 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cluster headache prophylaxis (off-label use):</b> Oral: Initial: 25 mg daily, titrated at weekly intervals in 25 mg increments, up to 200 mg daily (Pascual 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Essential tremor (off-label use):</b> Oral: Initial: 25 mg once daily; increase dose at weekly intervals based on response and tolerability in 25 mg increments up to 100 mg/day and then in 50 mg increments up to 400 mg/day (Ondo 2006). Alternatively, once 200 mg/day is achieved, doses may be increased weekly in 100 mg increments up to 400 mg/day (Connor 2008). For dosages &ge;50 mg/day administer in 2 divided doses (Ondo 2006). Average doses in clinical trials were 292 mg/day (median: 375 mg/day) (Ondo 2006) and 215 mg/day (range: 25 to 400 mg/day) (Connor 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Status epilepticus, refractory (off-label use):</b> Oral, NG: Initial: 200 to 400 mg; maintenance: 300 to 1600 mg in 2 to 4 divided doses (NCS [Brophy 2012]). Additional data is necessary to further define the role of topiramate in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229228\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=topiramate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Topiramate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects. Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Epilepsy, monotherapy:</b> Partial-onset seizure and primary generalized tonic-clonic seizure:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;10 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 25 mg once daily (in evening); may increase to 25 mg twice daily in week 2; thereafter, may increase by 25 to 50 mg daily at weekly intervals over 5 to 7 weeks up to the following minimum recommended maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;11 kg: 150 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to 22 kg: 200 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">23 to 31 kg: 200 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">32 to 38 kg: 250 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;39 kg: 250 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maximum maintenance dose: If additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg daily at weekly intervals up to the following maximum recommended maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;11 kg: 250 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to 22 kg: 300 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">23 to 31 kg: 350 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">32 to 38 kg: 350 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;39 kg: 400 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Qudexy XR only):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 25 mg once daily (in the evening); if tolerated, may increase to 50 mg once daily in week 2; thereafter, may increase by 25 to 50 mg daily at weekly intervals over 5 to 7 weeks up to the following minimum recommended maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;11 kg: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to 31 kg: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;32 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maximum maintenance dose: If additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg daily at weekly intervals up to the following maximum recommended maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;11 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to 22 kg: 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">23 to 38 kg: 350 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;38 kg: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to &lt;10 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Trokendi XR only):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: 25 mg once daily (in the evening); if tolerated, may increase to 50 mg once daily in week 2; thereafter, may increase by 25 to 50 mg daily at weekly intervals over 5 to 7 weeks up to the following minimum recommended maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;11 kg: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to 31 kg: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;32 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maximum maintenance dose: If additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg daily at weekly intervals up to the following maximum recommended maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;11 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12 to 22 kg: 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">23 to 38 kg: 350 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;38 kg: 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Epilepsy, adjunctive therapy:</b> Partial-onset seizure, primary generalized tonic-clonic seizure, or Lennox-Gastaut syndrome:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;6 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 25 mg (1 to 3 mg/kg/day) once daily (in evening) for 1 week; may increase every 1 to 2 weeks in increments of 1 to 3 mg/kg/day up to the recommended dose of 5 to 9 mg/kg/day in 2 divided doses; maximum dose: 400 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Qudexy XR only): Initial: 25 mg (1 to 3 mg/kg/day) once daily (in evening) for 1 week; may increase every 1 to 2 weeks in increments of 1 to 3 mg/kg/day up to the recommended dose of 5 to 9 mg/kg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and Adolescents &lt;17 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 25 mg (1 to 3 mg/kg/day) once daily (in evening) for 1 week; may increase every 1 to 2 weeks in increments of 1 to 3 mg/kg/day up to the recommended dose of 5 to 9 mg/kg/day in 2 divided doses; maximum dose: 400 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Qudexy XR and Trokendi XR): Initial: 25 mg (1 to 3 mg/kg/day) once daily (in evening) for 1 week; may increase every 1 to 2 weeks in increments of 1 to 3 mg/kg/day up to the recommended dose of 5 to 9 mg/kg once daily; maximum dose: 400 mg/day (Trokendi XR).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;17 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Migraine prophylaxis:</b> Adolescents &ge;12 years: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infantile spasms (off-label use):</b> Oral: Limited data available; dosing regimens variable. Consider twice-daily therapy once dose titration begins:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Newly diagnosed infantile spasm:</i> Weight-directed dosing: Infants and Children 3 to 24 months: Immediate release: Initial: 1 to 3 mg/kg/day administered as 1 or 2 daily doses; titrate every 3 to 7 days in 1 to 3 mg/kg/day increments as tolerated until seizures controlled; reported mean dose range: 9.1 to 14 mg/kg/day; reported range: 4 to 27 mg/kg/day. Dosing based on 2 small studies; first was an open-label trial of 15 pediatric patients (mean age: 8 months; age range: 4 to 14 months) with newly diagnosed infantile spasms that used an initial dose of 3 mg/kg/day in 2 divided doses; doses were increased by 3 mg/kg/day every 3 days until seizures were controlled or toxicity developed; mean dose required: 14 mg/kg/day (9 to 27 mg/kg/day); median rate of spasm reduction was 41% within the first 2 months of therapy with 20% of patients becoming spasm free (three of 15 patients) and 33% achieving a 50% reduction in spasm frequency (five of 15 patients) (Hosain 2006). In another trial of 20 pediatric patients (median age: 6.5 months; range: 3 to 24 months) with newly diagnosed infantile spasms, an initial dose of 1 mg/kg/day was used; dose was increased by 1 mg/kg/day at weekly intervals until seizures were controlled up to a maximum daily dose: 12 mg/kg/day; reported mean stabilizing dose: 9.1 mg/kg/day (4 to 12 mg/kg/day); results showed 30% of patients became spasm free (six of 20 patients) and 70% achieved at least a 50% reduction in spasm frequency (Kwon 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Refractory:</i> Fixed dosing: Infants &ge;3 months to Children &le;4 years; weight &ge;7 kg: Immediate release: Initial: 25 mg/day once daily; titrate in 25 mg/day increments every 2 to 3 days as tolerated until seizures controlled up to a maximum daily dose: 24 mg/kg/day; dosing is from an open-label trial of 11 pediatric patients (mean age: 24 months) that reported a mean stabilizing dose of 15 mg/kg/day (8.3 to 23.7 mg/kg/day); results showed statistically significant decrease in spasm frequency with 45% of patients becoming spasm free (Glauser 1998a). In an extension phase of this study in eight of the initial subjects, the mean dose was 29 mg/kg/day (maximum daily dose: 50 mg/kg/day); 50% of the remaining patients (four of eight) were seizure free and all patients except one maintained a &ge;50% reduction in spasm frequency (Glauser 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229212\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Most older adults have creatinine clearances &lt;70 mL/minute/1.73 m<sup>2</sup>; obtain a serum creatinine and calculate creatinine clearance prior to initiation of therapy. An initial dose of 25 mg/day may be recommended, followed by incremental increases of 25 mg at weekly intervals until an effective dose is reached; refer to adult dosing for titration schedule.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229213\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;70 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;70 mL/minute/1.73 m<sup>2</sup>: Reduce dose to 50% of normal dose and titrate more slowly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: 50 to 100 mg twice daily; administer a supplemental dose (50 to 100 mg) post-dialysis (Israni 2006). Topiramate is cleared by hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229214\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, topiramate clearance in hepatic impairment may be reduced. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229180\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule ER 24 Hour Sprinkle, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qudexy XR: 25 mg (30 ea, 500 ea [DSC]); 50 mg (30 ea, 500 ea [DSC]); 100 mg (30 ea, 500 ea [DSC]); 150 mg (30 ea, 500 ea [DSC]); 200 mg (30 ea, 500 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg (30 ea, 500 ea [DSC]); 50 mg (30 ea, 500 ea [DSC]); 100 mg (30 ea, 500 ea [DSC]); 150 mg (30 ea, 500 ea [DSC]); 200 mg (30 ea, 500 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trokendi XR: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trokendi XR: 50 mg, 100 mg, 200 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Sprinkle, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topamax Sprinkle: 15 mg, 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topamax: 25 mg, 50 mg, 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topiragen: 25 mg [DSC], 50 mg [DSC], 100 mg [DSC], 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229165\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874884\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Qudexy XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205122s003s005lbl.pdf#page=69&amp;token=mS8d2NOSGey35PLAjNd4z5jDHRYbqVWPRv6db+Nn+7A2T8GCHpkcFaH5C9afxvNIZ4NMIPayD6jHU4Y8YuiMi4LvJCWBy1UVXe9t9e5oZLc2SXRQ+b7brw40CMUT1yoJ&amp;TOPIC_ID=10006\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205122s003s005lbl.pdf#page=69</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topamax: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf#page=50&amp;token=DsUtD28FbtieUqHJ3rW8dUtaS/738nzWLlICLUHiBZ4QkatkmrjfjcIfZVyOSZI4Mczaq45H5GRZzc+yuWEKbkCDNZSyLHqH3+wVFwh9lGrA2kDzb2IlVMPfvVl2PXfQ&amp;TOPIC_ID=10006\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf#page=50</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trokendi XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201635s011s017lbl.pdf#page=58&amp;token=vpXvHZAcwGX+kcnVpwuXisDFCgneVP2MNpYNTUnIyXdc4ym+3pO/bLVpq6j0RLoy5GdL/e/kDqN4y0gdBo0g6pClMiFISmbFB+VUoac/8tydzjZ4UL04fNHXnLtlkTRJ&amp;TOPIC_ID=10006\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201635s011s017lbl.pdf#page=58</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229184\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals. Administer the immediate release formulation in divided doses. It is not recommended to crush, break, or chew immediate release tablets due to bitter taste. Swallow extended release (ER) and sprinkle capsules whole. Sprinkle capsules and Qudexy XR capsules may also be opened to sprinkle the entire contents on a small amount (~1 teaspoon) of soft food; swallow immediately and do not chew. Do not store drug/food mixture for future use. Do not sprinkle Trokendi XR capsules on food, chew, or crush. Avoid alcohol use with Trokendi XR capsules within 6 hours prior to and 6 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132845\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229183\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epilepsy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monotherapy: As initial monotherapy in patients &ge;2 years (immediate release and Qudexy XR) or &ge;6 years (Trokendi XR) with partial-onset or primary generalized tonic-clonic seizures</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjunctive therapy: As adjunctive therapy in patients &ge;2 years (immediate release and Qudexy XR) or &ge;6 years (Trokendi XR only) with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine:</b> Prophylaxis of migraine headache in patients &ge;12 years.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744919\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Alcohol dependence; Antipsychotic-induced weight gain; Binge eating disorder; Borderline personality disorder; Bulimia nervosa; Cluster headache (prophylaxis); Essential tremor; Infantile spasms; Status epilepticus, refractory (adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229250\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Topamax may be confused with Sporanox, TEGretol, TEGretol-XR, Toprol-XL</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Qudexy XR capsules may be opened to sprinkle the entire contents on a small amount (~1 teaspoon) of soft food. Do not open and sprinkle Trokendi XR capsules on food, chew, or crush; doing so may disrupt the tri-phasic release properties.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Avoid alcohol use with Trokendi XR within 6 hours prior to and 6 hours after administration; concurrent use may result in dose dumping.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229172\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events are reported for adult and pediatric patients for various indications and regimens. <b>Note:</b> A wide range of dosages were studied. Incidence of adverse events was frequently lower in the pediatric population studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (adolescents &amp; adults: 19% to 51%; children &amp; adolescents: 3% to 12%), fatigue (8% to 15%), drowsiness (adolescents &amp; adults: 6% to 15%), dizziness (adolescents &amp; adults: 6% to 14%), memory impairment (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum bicarbonate (adolescents &amp; adults: 14% to 77%; children &amp; adolescents: 9% to 25%; &gt;5 mEq/L to &lt;17 mEq/L: 1% to 11%), hyperammonemia (adolescents: 14% to 26%; &ge;50% above ULN [adolescents]: 9%), weight loss (4% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (adolescents &amp; adults: 6% to 15%), anorexia (adolescents &amp; adults: 4% to 15%), dysgeusia (adolescents &amp; adults: 3% to 15%), nausea (adolescents &amp; adults: 8% to 13%), diarrhea (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (13% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (children &amp; adolescents: &le;5%), chest pain (adults: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Disturbance in attention (&le;10%), lack of concentration (&le;10%), depression (adults: 7% to 9%; children &amp; adolescents: &le;3%), insomnia (adolescents &amp; adults: 6% to 9%), mood disorder (1% to 8%), hypoesthesia (adolescents &amp; adults 4% to 7%), anxiety (adolescents &amp; adults: 4% to 6%), cognitive dysfunction (1% to 6%), psychomotor retardation (adolescents &amp; adults: 2% to 5%), headache (children and adolescents: 4%), nervousness (adolescents &amp; adults: 4%), ataxia (adolescents &amp; adults: 1% to 4%), behavioral problems (children &amp; adolescents: &le;3%), confusion (&le;3%), hypertonia (adults: &le;3%), vertigo (children and adolescents: &le;3%), agitation (adolescents &amp; adults: 2%), exacerbation of depression (adolescents &amp; adults: 2%), speech disturbance (adolescents &amp; adults: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (1% to 4%), pruritus (adolescents &amp; adults: 1% to 4%), skin rash (1% to 4%), acne vulgaris (adults: 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease (adolescents &amp; adults: 3%), intermenstrual bleeding (children and adolescents: &le;3%), increased gamma-glutamyl transferase (adults: 1% to 3%), increased thirst (adolescents &amp; adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (adolescents &amp; adults: 4% to 5%), constipation (adolescents &amp; adults: 1% to 4%), gastroenteritis (adolescents &amp; adults: 3%), gastritis (adults: &le;3%), xerostomia (adolescents &amp; adults: 1% to 3%), gastroesophageal reflux disease (adults: 1% to 2%), ageusia (adolescents &amp; adults: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (adolescents &amp; adults: 1% to 4%), premature ejaculation (adolescents &amp; adults: 3%), decreased libido (adults: &le;3%), urinary frequency (&le;3%), vaginal hemorrhage (adults: &le;3%), cystitis (adults: 1% to 3%), urinary incontinence (children &amp; adolescents: 1% to 3%), dysuria (adults: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (4% to 5%), anemia (children &amp; adolescents: 1% to 3%), neoplasm (adolescents &amp; adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (adolescents &amp; adults: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (3% to 8%), infection (2% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (adolescents &amp; adults: 3% to 7%), weakness (&le;6%), muscle spasm (&le;3%), leg pain (adolescents &amp; adults: 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (adolescents &amp; adults: 2% to 7%), blurred vision (adolescents &amp; adults: 4%), visual disturbance (adolescents &amp; adults: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media (adolescents &amp; adults: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Nephrolithiasis (adolescents &amp; adults: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinusitis (1% to 10%), cough (adolescents &amp; adults: 2% to 7%), rhinitis (2% to 7%), pharyngitis (adolescents &amp; adults: 5% to 6%), bronchitis (1% to 5%), epistaxis (children and adolescents: &le;4%), dyspnea (adolescents &amp; adults: 1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (adolescents &amp; adults: 9%), language problems (adolescents &amp; adults: 6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension, orthostatic hypotension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Attempted suicide, suicidal ideation, suicidal tendencies</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperchloremia (children &amp; adolescents), increased serum total protein (children &amp; adolescents), increased uric acid (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gingival hemorrhage, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Abnormal phosphorus levels (decreased; children &amp; adolescents), change in platelet count (increased; children &amp; adolescents), decreased neutrophils (children &amp; adolescents), decreased white blood cell count (children &amp; adolescents), eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Myopia, scotoma, visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (children &amp; adolescents), increased serum creatinine (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute myopia with secondary angle-closure glaucoma, bullous rash, erythema multiforme, hepatic failure, hepatitis, hyperammonemic encephalopathy, hyperchloremic metabolic acidosis (nonanion gap), hyperthermia, hypohidrosis, maculopathy, major hemorrhage (children), pancreatitis, pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229187\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Recent alcohol use (ie, within 6 hours prior to and 6 hours after administration) (Trokendi XR only); patients with metabolic acidosis who are taking concomitant metformin (Qudexy XR only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to topiramate or any component of the formulation or container; pregnancy and women in childbearing years not using effective contraception (migraine prophylaxis only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229169\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Cognitive dysfunction (confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems), psychiatric disturbances (depression or mood disorders), and sedation (somnolence or fatigue) may occur with use; incidence may be related to rapid titration and higher doses; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May also cause paresthesia, dizziness, and ataxia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperammonemia/encephalopathy: Hyperammonemia with or without encephalopathy may occur with monotherapy or in combination with valproic acid and has been documented in patients who have tolerated each drug alone; incidence may be dose-related. Risk may be increased in patients with inborn errors of metabolism or decreased hepatic mitochondrial activity. May be asymptomatic; monitor for lethargy, vomiting, or unexplained changes in mental status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic acidosis: May be associated with hyperchloremic nonanion gap metabolic acidosis due to inhibition of carbonic anhydrase and increased renal bicarbonate loss. Decreases in serum bicarbonate are relatively common (up to 67% of epilepsy patients and 77% of migraine patients) but usually mild-to-moderate (average decrease of 4 mEq/L at dose of 400 mg/day in adults and 6 mg/kg/day in children). However, risk may be increased in patients with a predisposing condition (renal, respiratory and/or hepatic impairment), diarrhea, ketogenic diet, status epilepticus, or concurrent treatment with other drugs which may cause acidosis. Metabolic acidosis may occur at dosages as low as 50 mg/day. Serum bicarbonate should be monitored, as well as potential complications of chronic acidosis (nephrolithiasis, nephrocalcinosis, osteomalacia/osteoporosis, and reduced growth rates and/or reduced weight in children). Dose reduction or discontinuation (by tapering dose) should be considered in patients with persistent or severe metabolic acidosis. If treatment is continued, alkali supplementation should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligohidrosis/hyperthermia: May be associated with oligohidrosis and hyperthermia, most frequently in children; use caution and monitor closely during strenuous exercise, during exposure to high environmental temperature, or in patients receiving other carbonic anhydrase inhibitors and drugs with anticholinergic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Has been associated with acute myopia and secondary angle-closure glaucoma in adults and children, typically within 1 month of initiation; discontinue in patients with acute onset of decreased visual acuity and/or ocular pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal calculus: Topiramate exhibits weak carbonic anhydrase inhibitory properties and may increase the risk of kidney stones about 2 to 4 times that of the untreated population. Kidney stones have been reported in children and adults (incidence higher in males). Consider avoiding use in patients on a ketogenic diet. The risk of kidney stones may be reduced by increasing fluid intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual field defects: Has been reported independent of increased intraocular pressure; generally reversible upon discontinuation. Consider discontinuation if visual problems occur at any time during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression or suicidal tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eating disorders: The exacerbation and development of eating disorders, including anorexia nervosa and bulimia, has been reported in case reports of adolescents receiving topiramate for migraines or chronic headaches and an adult receiving topiramate for epilepsy. Prior to initiation of topiramate screen for a history of eating disorder symptoms, eating disorder risk factors (eg, history of dieting behavior), cognitive symptoms of eating disorders (eg, weight or shape concerns, fear of gaining weight, drive for thinness), and any recent changes in social functioning including increased withdrawal or isolation. Inquire whether the patient has unrealistic or unhealthy weight goals. Evaluate exercise habits (eg, look for over-exercising or compulsive exercising above that of similarly athletic peers) and dietary intake; assess rigid patterns or avoidance of specific categories of foods and preoccupation with maintaining a &ldquo;healthy diet&rdquo; or experimentation with fad diets. In adolescents assess developmental weight history with growth curves. Monitor eating behaviors and weight closely in patients receiving topiramate who have eating disorder symptoms or risk factors (Lebow 2015; Rosenow 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution with hepatic impairment; clearance may be reduced. Dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution with renal impairment; clearance may be reduced. Dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; dosage adjustment may be necessary. Weight loss, cognitive impairment, sedation, and gait/balance disturbances may be more pronounced in the older adult cohort (Sommer 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Do not discontinue abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Doses were also gradually withdrawn in migraine prophylaxis studies (decreased in weekly intervals by 25-50 mg/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229235\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229174\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10006&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR).  Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval. Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated.  Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Topiramate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Topiramate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Topiramate may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hypokalemic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Topiramate may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Topiramate may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: Topiramate may decrease the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Topiramate may decrease the serum concentration of Progestins (Contraceptive).  Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate. Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Topiramate may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Topiramate may enhance the adverse/toxic effect of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229202\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Ketogenic diet may increase the possibility of acidosis and/or kidney stones. Management: Monitor for symptoms of acidosis or kidney stones.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229176\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229191\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on limited data (n=5), topiramate was found to cross the placenta and could be detected in neonatal serum (Ohman 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Topiramate may cause fetal harm if administered to a pregnant woman. An increased risk of oral clefts (cleft lip and/or palate) and for being small for gestational age (SGA) has been observed following in utero exposure. Data from the North American Antiepileptic Drug (NAAED) Pregnancy Registry reported that the prevalence of oral clefts was 1.1% for infants exposed to topiramate during the first trimester of pregnancy, versus 0.36% for infants exposed to a reference antiepileptic drug, and 0.12% for infants with no exposure born to mothers without epilepsy; the relative risk of oral clefts in infants exposed to topiramate was calculated to be 9.6 (95% CI: 4 to 23). Data from the NAAED Pregnancy Registry reported that the prevalence of small for gestational age newborns was 19.7% for newborns exposed to topiramate in utero, versus 7.9% for newborns exposed to a reference antiepileptic drug, and 5.4% for newborns with no exposure born to mothers without epilepsy. Although not evaluated during pregnancy, metabolic acidosis may be induced by topiramate. Metabolic acidosis during pregnancy may result in adverse effects and fetal death. Pregnant women and their newborns should be monitored for metabolic acidosis. In general, maternal polytherapy with antiepileptic drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of women taking antiepileptic medications may be at an increased risk of a 1 minute APGAR score &lt;7 (Harden 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Maternal serum concentrations may decrease during the second and third trimesters of pregnancy; therefore, therapeutic drug monitoring should be considered during pregnancy and postpartum in patients who require therapy (Ohman 2009; Westin 2009). Effective contraception should be used in women who are not planning a pregnancy; consider use of alternative medications in women who wish to become pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to topiramate is ongoing. Patients may enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229192\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Topiramate is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of topiramate is ~3% to 23% when calculated using a range of breast milk concentrations obtained from three lactating women and compared to a weight-adjusted maternal dose of 150 to 200 mg/day (Ohman 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10%; when the RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of topiramate was calculated using a range of milk concentrations of 1.6 to 14.6 micromolar, providing an estimated daily infant dose via breast milk of ~0.1 to 0.7 mg/kg/day. These milk concentrations were obtained following maternal administration of oral topiramate 150 to 200 mg/day in three women 2 weeks' to 3 months' postpartum; concomitant medications included carbamazepine or valproic acid, both of which may have had an impact on maternal serum concentrations. Topiramate was detected in the plasma of the breastfed infants at ~10% to 20% of the maternal plasma concentration (Ohman 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Diarrhea has been reported in an infant exposed to topiramate via breast milk; resolution of diarrhea occurred 2 days after breastfeeding was stopped (Westergren 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229178\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Seizure frequency, hydration status; electrolytes (recommended monitoring includes serum bicarbonate at baseline and periodically during treatment), serum creatinine; monitor for symptoms of acute acidosis and complications of long-term acidosis (nephrolithiasis, nephrocalcinosis, osteomalacia/osteoporosis, and reduced growth rates and/or weight in children); ammonia level in patients with unexplained lethargy, vomiting, or mental status changes; intraocular pressure, symptoms of secondary angle closure glaucoma; suicidality (eg, suicidal thoughts, depression, behavioral changes); weight and eating behaviors in patients with eating disorder symptoms or risk factors; sedation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229168\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Anticonvulsant activity may be due to a combination of potential mechanisms: Blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229186\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Immediate release preparations are bioequivalent (sprinkle capsule and tablet); extended release capsules (Trokendi XR) administered once daily is bioequivalent to twice daily administration of immediate release formulations. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Good, rapid; immediate release formulation is unaffected by food. A single Trokendi XR dose with a high-fat meal increased the C<sub>max</sub> by 37% and shortened the T<sub>max</sub> to approximately 8 hours; this effect is significantly reduced following repeat administrations. A single Qudexy XR dose with a high-fat meal delayed the T<sub>max</sub> by 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d:</sub> 0.6 to 0.8 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 15% to 41% (inversely related to plasma concentrations) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minor amounts metabolized in liver via hydroxylation, hydrolysis, and glucuronidation; there is evidence of renal tubular reabsorption; percentage of dose metabolized in liver and clearance are increased in patients receiving enzyme inducers (eg, carbamazepine, phenytoin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~80% (immediate release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Not receiving concomitant enzyme inducers or valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Neonates (full-term) with hypothermia: ~43 hours (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 10.4 hours (range: 8.5 to 15.3 hours) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 4 to 7 years: Mean range: 7.7 to 8 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 8 to 11 years: Mean range: 11.3 to 11.7 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents 12 to 17 years: Mean range: 12.3 to 12.8 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Receiving concomitant enzyme inducers (eg, carbamazepine, phenytoin, phenobarbital):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\"> Neonates (full-term) with hypothermia: 26.5 hours (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 6.5 hours (range: 3.75 to 10.2 hours) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents 4 to 17 years: 7.5 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Receiving valproic acid: Infants and Children 9 months to 4 years: 9.2 hours (range: 7.23 to 12 hours) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 19 to 23 hours (mean: 21 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults with renal impairment: 59 &plusmn; 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Qudexy XR: ~56 hours; Trokendi XR: ~31 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates (full-term) with hypothermia: 3.8 hours (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 3.7 hours (range: 1.5 to 10.2 hours) (Michealoff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 4 to 17 years: Mean range: 1 to 2.8 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 2 hours; range: 1.4 to 4.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Qudexy XR: ~20 hours; Trokendi XR: ~24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% as unchanged drug); may undergo renal tubular reabsorption </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Not receiving concomitant enzyme inducers or valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates (full-term) with hypothermia: 13.4 mL/kg/hour (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 46.5 mL/kg/hour (range: 30.5 to 70.9 mL/kg/hour) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 4 to 17 years: 27.6 mL/kg/hour (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Receiving concomitant enzyme inducers: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates (full-term) with hypothermia: 17.9 mL/kg/hour (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 85.4 mL/kg/hour (range: 46.2 to 135 mL/kg/hour) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents 4 to 17 years: 60.6 mL/kg/hour (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Receiving valproic acid: Infants and Children 9 months to &lt;4 years: 49.6 mL/kg/hour (range: 26.6 to 60.2 mL/kg/h) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 20 to 30 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229190\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Sprinkle</b> (Qudexy XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $255.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $332.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $659.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $811.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $902.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Sprinkle</b> (Topiramate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $215.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $280.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $556.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $683.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $760.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Trokendi XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $318.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $415.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $822.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $1,124.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Topamax Sprinkle Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $387.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $468.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Topiramate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $144.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $175.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Topamax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $409.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $817.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $1,116.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,307.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Topiramate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $152.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $302.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $413.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $483.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229193\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acomicil (ES);</li>\n      <li>Epilramate (TW);</li>\n      <li>Epimat (UA);</li>\n      <li>Epimate (LK, PH);</li>\n      <li>Epitomax (FI, FR);</li>\n      <li>Epitop (PH);</li>\n      <li>Etopira (BD);</li>\n      <li>Fagodol (ES);</li>\n      <li>Gabatopa (KR);</li>\n      <li>Ipramax (QA);</li>\n      <li>Moramax (TH);</li>\n      <li>Piramed (BD);</li>\n      <li>Pradox (TH);</li>\n      <li>Rondigal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Seziril (LK);</li>\n      <li>Tamate (AU);</li>\n      <li>Tiramate (NZ);</li>\n      <li>Topamac (AR, CO, EC, IN, PE, PY, UY);</li>\n      <li>Topamaks (UA);</li>\n      <li>Topamax (AE, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, EE, EG, ES, FI, GB, HK, HR, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, LY, MT, MX, MY, NL, NZ, OM, PH, PK, PL, PT, QA, RO, RU, SA, SG, SI, SK, SY, TH, TR, TW, VE, VN, YE, ZA);</li>\n      <li>Topamax Sprinkle (AE, BB, BH, CY, HK, IL, KR, KW, NZ, SA);</li>\n      <li>Topictal (CR, DO, EC, GT, HN, NI, PA, PY, SV);</li>\n      <li>Topimax (CR, DK, DO, GT, HN, IS, NI, NO, PA, SE, SV);</li>\n      <li>Topina (JP);</li>\n      <li>Topinmate (TW);</li>\n      <li>Topirol (PH);</li>\n      <li>Topiron (KR);</li>\n      <li>Topirva (BD);</li>\n      <li>Topitrim (IL);</li>\n      <li>Topmate (BD, KR);</li>\n      <li>Topomac (GR);</li>\n      <li>Toprakar (UA);</li>\n      <li>Topvex (PH);</li>\n      <li>Toramate (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apo-Topiramate [product monograph]. Toronto, Ontario, Canada: Apotex; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14698713\"></a>Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. <i>Epilepsy Behav</i>. 2003;4(6):757-760.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/14698713/pubmed\" target=\"_blank\" id=\"14698713\">14698713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blaszczyk AT, Hutchison LC. Central Nervous System Disorders. <i>Fundamentals of Geriatric Pharmacotherapy, 2</i><sup>nd</sup><i> edition.</i> Hutchison LC, Sleeper RB, Eds. ASHP Publications; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al. Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. <i>Neurology</i>. 2011;76(20):1758-1765.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carroll DG, Kline KM, and Malnar KF, &quot;Role of Topiramate for the Treatment of Painful Diabetic Peripheral Neuropathy,&quot; <i>Pharmacotherapy</i>, 2004, 24(9):1186-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15460179/pubmed\" target=\"_blank\" id=\"15460179\">15460179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chong MS and Libretto SE, &quot; The Rationale and Use of Topiramate for Treating Neuropathic Pain,&quot; <i>Clin J Pain</i>, 2003, 19(1):59-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12514458/pubmed\" target=\"_blank\" id=\"12514458\">12514458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. <i>Clinical Neuropharmacology</i>. 2008;31(2):97-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/18382182/pubmed\" target=\"_blank\" id=\"18382182\">18382182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Das C, Mendez G, Jagasia S, Labbate LA. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. <i>Ann Clin Psychiatry</i>. 2012;24(3):225-239.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/22860242/pubmed\" target=\"_blank\" id=\"22860242\">22860242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dib JG, &quot;Focus on Topiramate in Neuropathic Pain,&quot; <i>Curr Med Res Opin</i>, 2004, 20(12):1857-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15701203/pubmed\" target=\"_blank\" id=\"15701203\">15701203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doose DR, Walker SA, Gisclon LG, et al, &ldquo;Single-Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, a Novel Antiepileptic Drug,&rdquo; <i>J Clin Pharmacol</i>, 1996, 36(10):884-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/8930774/pubmed\" target=\"_blank\" id=\"8930774\">8930774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. <i>Pain</i>. 2007;132(3):237-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/17920770/pubmed\" target=\"_blank\" id=\"17920770\">17920770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. <i>Curr Psychiatry Rev</i>. 2012;8(1):25-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/22712004/pubmed\" target=\"_blank\" id=\"22712004\">22712004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filippi L, la Marca G, Fiorini P, et al, &quot;Topiramate Concentrations in Neonates Treated With Prolonged Whole Body Hypothermia for Hypoxic Ischemic Encephalopathy,&quot; <i>Epilepsia</i>, 2009, 50(11):2355-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/19744111/pubmed\" target=\"_blank\" id=\"19744111\">19744111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Clark PO, and Strawsburg R, &ldquo;A Pilot Study of Topiramate in the Treatment of Infantile Spasms,&rdquo; <i>Epilepsia</i>, 1998a, 39(12):1324-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/9860068/pubmed\" target=\"_blank\" id=\"9860068\">9860068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, &ldquo;Preliminary Observations on Topiramate in Pediatric Epilepsies,&rdquo; <i>Epilepsia</i>, 1997, 38(Suppl 1):37-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/9092958/pubmed\" target=\"_blank\" id=\"9092958\">9092958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, &ldquo;Topiramate Use in Pediatric Patients,&rdquo; <i>Can J Neurol Sci</i>, 1998b, 25(3):S8-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/9706734/pubmed\" target=\"_blank\" id=\"9706734\">9706734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Groselj J, Guerrini R, Van Oene J, et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. <i>Acta Neurol Scand.</i> 2005;112:144-150. doi: 10.1111/j.1600-0404.2005.00469.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/16097955/pubmed\" target=\"_blank\" id=\"16097955\">16097955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. <i>J Clin Psychiatry</i>. 2003;64(12):1449-1454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/14728106/pubmed\" target=\"_blank\" id=\"14728106\">14728106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17963189\"></a>Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, M&ouml;ller HJ; WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. <i>World J Biol Psychiatry</i>. 2007;8(4):212-244. doi: 10.1080/15622970701685224<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/17963189/pubmed\" target=\"_blank\" id=\"17963189\">17963189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershey AD, Powers SW, Vockell AL, et al, &ldquo;Effectiveness of Topiramate in the Prevention of Childhood Headaches,&rdquo; <i>Headache</i>, 2002, 42(8):810-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12390646/pubmed\" target=\"_blank\" id=\"12390646\">12390646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. <i>J Clin Psychiatry</i>. 2003;64(11):1335-1341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/14658948/pubmed\" target=\"_blank\" id=\"14658948\">14658948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. <i>Semin Dial</i>. 2006;19(5):408-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/16970741/pubmed\" target=\"_blank\" id=\"16970741\">16970741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. <i>Arch Gen Psychiatry</i>. 2004;61(9):905-912. doi: 10.1001/archpsyc.61.9.905<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15351769/pubmed\" target=\"_blank\" id=\"15351769\">15351769</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. <i>JAMA</i>. 2007;298(14):1641-1651. doi: 10.1001/jama.298.14.1641<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/17925516 /pubmed\" target=\"_blank\" id=\"17925516 \">17925516 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ko Y-H, Joe S-H, Jung I-K, Kim S-H. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. <i>Clin Neuropharmacol. </i>2005;28:169-175.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krymchantowski AV, Bigal ME, and Moreira PR, &ldquo;New and Emerging Prophylactic Agents for Migraine,&rdquo; <i>CNS Drugs</i>, 2002, 16(9):611-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12153333/pubmed\" target=\"_blank\" id=\"12153333\">12153333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwon YS, Jun YH, Hong YJ, Son BK. Topiramate monotherapy in infantile spasm. <i>Yonsei Med J</i>. 2006;47(4):498-504. doi: 10.3349/ymj.2006.47.4.498<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/16941739/pubmed\" target=\"_blank\" id=\"16941739\">16941739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lebow J, Chuy JA, Cedermark K, Cook K, Sim LA. The development or exacerbation of eating disorder symptoms after topiramate initiation [published online ahead of print April 6, 2015]. <i>Pediatrics</i>. 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/25847809/pubmed\" target=\"_blank\" id=\"25847809\">25847809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20044651\"></a>Lieb K, V&ouml;llm B, R&uuml;cker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. <i>Br J Psychiatry</i>. 2010;196(1):4-12. doi: 10.1192/bjp.bp.108.062984. doi: 10.1192/bjp.bp.108.062984<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/20044651/pubmed\" target=\"_blank\" id=\"20044651\">20044651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16415708\"></a>Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. <i>J Clin Psychopharmacol</i>. 2006;26(1):61-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/16415708/pubmed\" target=\"_blank\" id=\"16415708\">16415708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahmood S, Booker I, Huang J, Coleman CI. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. <i>J Clin Psychopharmacol</i>. 2013;33(1):90-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/23277264/pubmed\" target=\"_blank\" id=\"23277264\">23277264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathew NT, Kailasam J, and Meadors L, &ldquo;Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache With Topiramate,&rdquo; <i>Headache</i>, 2002, 42(8):796-803.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12390644/pubmed\" target=\"_blank\" id=\"12390644\">12390644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial [published correction appears in <i>Am J Psychiatry</i>. 2003;160(3):612]. <i>Am J Psychiatry</i>. 2003;160(2):255-261. doi:10.1176/appi.ajp.160.2.255<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12562571/pubmed\" target=\"_blank\" id=\"12562571\">12562571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. <i>Biol Psychiatry</i>. 2007;61(9):1039-1048. doi:10.1016/j.biopsych.2006.08.008<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/17258690/pubmed\" target=\"_blank\" id=\"17258690\">17258690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntyre RS, Alsuwaidan M, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. <i>Ann Clin Psych. </i>2012;24(1):69-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/22303523/pubmed\" target=\"_blank\" id=\"22303523\">22303523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mikaeloff Y, Rey E, Soufflet C, et al, &quot;Topiramate Pharmacokinetics in Children With Epilepsy Aged From 6 Months to 4 Years,&quot; <i>Epilepsia</i>, 2004, 45(11):1448-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15509246/pubmed\" target=\"_blank\" id=\"15509246\">15509246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. <i>Schizophren Bull. </i>2014;40(6):1385-1403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/24636967/pubmed\" target=\"_blank\" id=\"24636967\">24636967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. <i>Schizophr Res</i>. 2010;118(1-3):218-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/20207521/pubmed\" target=\"_blank\" id=\"20207521\">20207521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15737664\"></a>Nickel MK, Nickel C, Kaplan P, Lahmann C, M&uuml;hlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. <i>Biol Psychiatry</i>. 2005a;57(5):495-499. doi: 10.1016/j.biopsych.2004.11.044<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15737664/pubmed\" target=\"_blank\" id=\"15737664\">15737664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15554765\"></a>Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. <i>J Clin Psychiatry</i>. 2004;65(11):1515-1519.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15554765/pubmed\" target=\"_blank\" id=\"15554765\">15554765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study. <i>J Clin Psychopharmacol. </i>2005b;25:211-217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15876898/pubmed\" target=\"_blank\" id=\"15876898\">15876898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Sabers A, de Flon P, et al, &quot;Pharmacokinetics of Topiramate During Pregnancy,&quot; <i>Epilepsy Res</i>, 2009, 87(2-3):124-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/19740626/pubmed\" target=\"_blank\" id=\"19740626\">19740626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Vitols S, Luef G, et al, &ldquo;Topiramate Kinetics During Delivery, Lactation, and in the Neonate: Preliminary Observations,&rdquo; <i>Epilepsia</i>, 2002, 43(10):1157-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12366729/pubmed\" target=\"_blank\" id=\"12366729\">12366729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. <i>Neurology</i>. 2006;66(5):672-677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/16436648/pubmed\" target=\"_blank\" id=\"16436648\">16436648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17355498\"></a>Pascual J, Lainez MJ, Dodick D, et al, &ldquo;Antiepileptic Drugs for the Treatment of Chronic and Episodic Cluster Headache: A Review,&rdquo; <i>Headache</i>, 2007, 47(1):81-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/17355498/pubmed\" target=\"_blank\" id=\"17355498\">17355498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qudexy XR (topiramate) [prescribing information]. Maple Grove, MN: Upsher-Smith; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11784388\"></a>Reuber M, Evans J, Bamford JM. Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol. 2002;9(1):111-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/11784388/pubmed\" target=\"_blank\" id=\"11784388\">11784388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld WE, Doose DR, Walker SA, et al, &quot;A Study of Topiramate Pharmacokinetics and Tolerability in Children With Epilepsy,&quot; <i>Pediatr Neurol</i>, 1999, 20(5):339-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/10371378/pubmed\" target=\"_blank\" id=\"10371378\">10371378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. <i>Am J Psychiatry</i>. 2002;159(12):2112-2113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12450969 /pubmed\" target=\"_blank\" id=\"12450969 \">12450969 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silberstein SD and Goadsby PJ, &ldquo;Migraine: Preventative Treatment,&rdquo; <i>Cephalalgia</i>, 2002, 22(7):491-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12230591/pubmed\" target=\"_blank\" id=\"12230591\">12230591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachdeo RC, &ldquo;Topiramate. Clinical Profile in Epilepsy,&rdquo; <i>Clin Pharmacokinet</i>, 1998, 34(5):335-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/9592618/pubmed\" target=\"_blank\" id=\"9592618\">9592618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sommer BR, Fenn HH. Review of topiramate for the treatment of epilepsy in elderly patients. <i>Clin Interv Aging.</i> 2010;5:89-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/20458347/pubmed\" target=\"_blank\" id=\"20458347\">20458347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20556762\"></a>Stoffers J, V&ouml;llm BA, R&uuml;cker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. <i>Cochrane Database Syst Rev</i>. 2010;(6):CD005653. doi: 10.1002/14651858.CD005653.pub2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/20556762/pubmed\" target=\"_blank\" id=\"20556762\">20556762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Story JR, Calder CS, Hart DE, et al, &ldquo;Topiramate in Migraine Prevention: A Double-Blind, Placebo-Controlled Study,&rdquo; <i>Headache</i>, 2001, 41(10):968-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/11903524/pubmed\" target=\"_blank\" id=\"11903524\">11903524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topamax (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12552056\"></a>Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. <i>Neurology</i>. 2003;60(2):332-334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12552056/pubmed\" target=\"_blank\" id=\"12552056\">12552056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trokendi XR (topiramate) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westergren T, Hjelmeland K, Kristoffersen B, Johannessen SI, Kalikstad B. Probable topiramate-induced diarrhea in a 2-month-old breast-fed child - a case report.<i> Epilepsy Behav Case Rep</i>. 2014;(2):22-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/25667861/pubmed\" target=\"_blank\" id=\"25667861\">25667861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westin AA, Nakken KO, Johannessen SI, et al, &quot;Serum Concentration/dose Ratio of Topiramate During Pregnancy,&quot; <i>Epilepsia</i>, 2009, 50(3):480-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/19178558/pubmed\" target=\"_blank\" id=\"19178558\">19178558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. <i>Cochrane Database Syst Rev</i>. 2013;8:CD008314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/23996081/pubmed\" target=\"_blank\" id=\"23996081\">23996081</a>]</span><span class=\"doi\">10.1002/14651858.CD008314.pub3</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yager J, Devlin MJ, Halmi KA, et al. Guideline watch (August 2012): practice guideline for the treatment of patients with eating disorders, 3<sup>rd</sup> edition. American Psychiatric Association Practice Guideline. 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young WB, Hopkins MM, Shechter AL, et al, &ldquo;Topiramate: A Case Series Study in Migraine Prophylaxis,&rdquo; <i>Cephalalgia</i>, 2002, 22(8):659-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/12383061/pubmed\" target=\"_blank\" id=\"12383061\">12383061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2011;77(19):1752-1755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/22013182/pubmed\" target=\"_blank\" id=\"22013182\">22013182</a>]</span><span class=\"doi\">10.1212/WNL.0b013e318236f0fd</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zesiewicz TA, Elble RJ, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2005;64(12):2008-2020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-drug-information/abstract-text/15972843/pubmed\" target=\"_blank\" id=\"15972843\">15972843</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10006 Version 266.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F229206\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F229207\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F229242\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F229211\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F229228\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F229212\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F229213\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F229214\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F229180\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F229165\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874884\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F229184\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132845\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F229183\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744919\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F229250\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F229172\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F229187\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F229169\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F229235\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F229174\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F229202\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F229176\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F229191\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F229192\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F229178\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F229168\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F229186\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F229190\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F229193\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10006|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=topiramate-patient-drug-information\" class=\"drug drug_patient\">Topiramate: Patient drug information</a></li><li><a href=\"topic.htm?path=topiramate-pediatric-drug-information\" class=\"drug drug_pediatric\">Topiramate: Pediatric drug information</a></li></ul></div></div>","javascript":null}